A review of JAK and IL-23 inhibitors to treat vitiligo

被引：4

作者：

Lee, Henry ^{[1
]}

Cowan, Timothy L. ^{[1
,2
]}

Daniel, Benjamin S. ^{[1
,2
]}

Murrell, Dedee F. ^{[1
,2
,3
]}

机构：

[1] Univ New South Wales, Fac Med, Sydney, NSW, Australia

[2] St George Hosp, Dept Dermatol, Sydney, NSW, Australia

[3] St George Hosp, Dept Dermatol, Gray St, Sydney, NSW 2217, Australia

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷 / 02期

关键词：

biologics; Interleukin-23; Janus kinase inhibitors; management; therapy; treatment; Vitiligo; NEW-ONSET VITILIGO; QUALITY-OF-LIFE; INFLAMMATORY-DISEASES; RUXOLITINIB CREAM; PLAQUE PSORIASIS; ALOPECIA-AREATA; 2-PHASE; TOFACITINIB; REPIGMENTATION; GUIDELINES;

D O I：

10.1111/ajd.14001

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Vitiligo is an autoimmune skin disorder resulting in the depigmentation of skin characterised by patches of varying sizes and shapes. A common disorder of pigmentation that affects 0.5%-2% of the global population. Despite its well-understood autoimmune pathogenesis, the targets for effective cytokine intervention remain unclear. Current first-line treatments include oral or topical corticosteroids, calcineurin inhibitors and phototherapy. These treatments are limited, have varying efficacies, and are associated with significant adverse events or can be time-consuming. Therefore, biologics should be explored as a potential treatment for vitiligo. There are currently limited data for the use of JAK and IL-23 inhibitors for vitiligo. A total of 25 studies were identified in the review. There is promising evidence regarding the use of JAK and IL-23 inhibitors for the treatment of vitiligo.

引用

页码：204 / 212

页数：9

共 69 条

[1]

AlMutairi N, 2019, J AM ACAD DERMATOL, V81, pAB109

[2] Drug-induced vitiligo: a case/non-case study in Vigibase(R), the WHO pharmacovigilance database [J].